| [1] |
Busse W,Corren J,Lanier BQ, et al.Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma[J]. J Allergy Clin Immunol, 2001, 108(2): 184-190.
|
| [2] |
Katz LE,Gleich GJ,Hartley BF, et al.Blood eosinophil count is a useful biomarker to identify patients with severe eosinophilic asthma[J]. Ann Am Thorac Soc, 2014, 11(4): 531-536.
|
| [3] |
Parulekar AD,Atik MA,Hanania NA.Periostin：a novel biomarker of TH2-driven asthma[J]. Curr Opin Pulm Med, 2014, 20(1): 60-65.
|
| [4] |
Corren J,Lemanske RF,Hanania NA, et al.Lebrikizumab treatment in adults with asthma[J]. N Engl J Med, 2011, 365(12): 1088-1098.
|
| [5] |
Bunyavanich S,Schadt EE.Systems biology of asthma and allergic diseases：a multiscale approach[J]. J Allergy Clin Immunol, 2015, 135(1): 31-42.
|
| [6] |
Keskin O,Balaban S,Keskin M, et al. Relationship between exhaled leukotriene and 8-isoprostane levels and asthma severity, asthma control level and asthma control test score[J]. Allergol Immunopathol(Madr), 2014, 42(3): 191-197.
|
| [7] |
Basu S. Bioactive eicosanoids：role of prostaglandin F(2alpha)and F(2)-isoprostanes in inflammation and oxidative stress related pathology[J]. Mol Cells, 2010, 30(5): 383-391.
|
| [8] |
Fatani SH.Biomarkers of oxidative stress in acute and chronic bronchial asthma[J]. J Asthma, 2014, 51(6): 578-584.
|
| [9] |
Agustí A,Edwards LD,Rennard SI, et al.Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) Investigators.Persistent systemic inflammation is associated with poor clinical outcomes in COPD：a novel phenotype[J]. PLoS One, 2012, 7(5): e37483.
|
| [10] |
Davidsen PK,Herbert JM,Antczak P, et al.A systems biology approach reveals a link between systemic cytokines and skeletal muscle energy metabolism in a rodent smoking model and human COPD[J]. Genome Med, 2014, 6(8): 59.
|
| [11] |
Donaldson A,Natanek SA,Lewis A, et al.Increased skeletal muscle-specific microRNA in the blood of patients with COPD[J]. Thorax, 2013, 68(12): 1140-1149.
|
| [12] |
Seimetz M,Parajuli N,Pichl A, et al.Inducible NOS inhibition reverses to bacco-smoke-induced emphysema and pulmonary hypertension in mice[J]. Cell, 2011, 147(2): 293-305.
|
| [13] |
Malhotra D,Thimmulappa RK,Mercado N, et al.Denitrosylation of HDAC2 by targeting Nrf2 restores glucocorticosteroid sensitivity in macrophages from COPD patients[J]. J Clin Invest, 2011, 121(11): 4289-4302.
|
| [14] |
Gamez AS,Gras D,Petit A, et al.Supplementing defect in club cell secretory protein attenuates airway inflammation in COPD[J]. Chest, 2015, 147(6): 1467-1476.
|
| [15] |
Lomas DA,Silverman EK,Edwards LD, et al.Evaluation of serum CC-16 as a biomarker for COPD in the ECLIPSE cohort[J]. Thorax, 2008, 63(12): 1058-1063.
|
| [16] |
Sand JM,Knox AJ,Lange P, et al.Accelerated extracellular matrix turnover during exacerbations of COPD[J]. Respir Res, 2015, 16(1): 69.
|
| [17] |
Liu X,Ma S,Liu S, et al.The ratio of free to bound desmosine and isodesmosine may reflect emphysematous changes in COPD[J]. Lung, 2015, 193(3): 329-334.
|
| [18] |
Ma S,Lin YY,He J, et al.Alpha-1 antitrypsin augmentation therapy and biomarkers of elastin degradation[J]. COPD, 2013, 10(4): 473-481.
|
| [19] |
Papakonstantinou E,Karakiulakis G,Batzios S, et al.Acute exacerbations of COPD are associated with significant activation of matrix metallo proteinase 9 irrespectively of airway obstruction, emphysema and infection[J]. Respir Res, 2015, 16(1): 78.
|
| [20] |
D’Armiento JM,Goldklang MP,Hardigan AA, et al.Increased matrix metalloproteinase (MMPs) levels do not predict disease severity or progression in emphysema[J]. PLoS One, 2013, 8(2): e56352.
|
| [21] |
Yeager ME,Nguyen CM,Belchenko DD, et al.Circulating fibrocytes are increased in children and young adults with pulmonary hypertension[J]. Eur Respir J, 2012, 39(1): 104-111.
|
| [22] |
Tamura Y,Ono T,Kuwana M, et al.Human pentraxin 3(PTX3) as a novel biomarker for the diagnosis of pulmonary arterial hypertension[J]. PLoS One, 2012, 7(9): e45834.
|
| [23] |
Santos M,Reis A,Goncalves F, et al.Adiponectin levels are elevated in patients with pulmonary arterial hypertension[J]. Clin Cardiol, 2014, 37(1): 21-25.
|
| [24] |
Rosenberg M,Meyer FJ,Gruenig E, et al. Osteopontin(OPN) improves risk stratification in pulmonary hypertension(PH) [J]. Int J Cardiol, 2012, 155(3): 504-505.
|
| [25] |
Wei L,Warburton RR,Preston IR, et al.Serotonylated fibronectin is elevated in pulmonary hypertension[J]. Am J Physiol Lung Cell Mol Physiol, 2012, 302(12): 1273-1279.
|
| [26] |
杨志寅. 现代医学科学发展中的缺憾和思考[J/CD]. 中华诊断学电子杂志, 2013, 1(1): 1-7.
|